Literature DB >> 31179546

HPV vaccination coverage and course completion rates for Indigenous Australian adolescents, 2015.

Julia Ml Brotherton1, Karen L Winch1, Genevieve Chappell1, Carolyn Banks2, Dennis Meijer3, Sonya Ennis3, Karen Peterson4, Rosalind Webby5, Lisa J Whop6.   

Abstract

OBJECTIVE: To estimate human papillomavirus (HPV) vaccination coverage and course completion rates for Indigenous adolescents in four Australian states and territories. PARTICIPANTS,
SETTING: Adolescents who were 12 years old in 2015 and received the quadrivalent HPV vaccine (three doses: 0, 2, 6 months) as part of the National HPV Vaccination Program in 2015 or 2016 in New South Wales, Queensland, the Northern Territory, or the Australian Capital Territory. MAIN OUTCOME MEASURES: Estimated HPV vaccination coverage by dose and by Indigenous status and sex, based on National HPV Vaccination Program Register data; vaccination course completion rates (proportion of dose 1 recipients who received dose 3) for 12-year-olds vaccinated during 2013-2016, by sex, jurisdiction, and Indigenous status.
RESULTS: Dose 1 coverage exceeded 80% for all Indigenous status/jurisdiction/sex groups (range, 83.3-97.7%). Coverage was similar for Indigenous and non-Indigenous girls in Queensland (87.3% v 87.0%), lower for Indigenous girls in the ACT (88.7% v 97.7%) and the NT (91.1% v 97.0%), and higher in NSW (95.9% v 89.9%); it was similar for Indigenous and non-Indigenous boys in all jurisdictions except the NT (88.6% v 96.3%). Dose 3 coverage (range, 61.2-87.7%) was markedly lower for Indigenous than non-Indigenous 12-year-olds in all jurisdictions, except for girls in NSW (82.6% v 83.6%).
CONCLUSION: HPV vaccine coverage is high, but course completion is generally lower for Indigenous adolescents. Strategies for improving completion rates for Indigenous Australians are needed to end the higher burden of cervical cancer among Indigenous than non-Indigenous women.
© 2019 AMPCo Pty Ltd.

Entities:  

Keywords:  Papillomavirus infections; Uterine cervical neoplasms; Vaccination

Mesh:

Substances:

Year:  2019        PMID: 31179546     DOI: 10.5694/mja2.50221

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  5 in total

1.  Elimination of cervical cancer: challenges for developing countries.

Authors:  Ann Marie Beddoe
Journal:  Ecancermedicalscience       Date:  2019-11-12

Review 2.  Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation.

Authors:  Arnaud John Kombe Kombe; Bofeng Li; Ayesha Zahid; Hylemariam Mihiretie Mengist; Guy-Armel Bounda; Ying Zhou; Tengchuan Jin
Journal:  Front Public Health       Date:  2021-01-20

Review 3.  HPV vaccine: uptake and understanding among global Indigenous communities - a qualitative systematic review.

Authors:  Brianna Poirier; Sneha Sethi; Gail Garvey; Joanne Hedges; Karen Canfell; Megan Smith; Xiangqun Ju; Lisa Jamieson
Journal:  BMC Public Health       Date:  2021-11-10       Impact factor: 3.295

4.  Measuring school level attributable risk to support school-based HPV vaccination programs.

Authors:  C Vujovich-Dunn; H Wand; J M L Brotherton; H Gidding; J Sisnowski; R Lorch; M Veitch; V Sheppeard; P Effler; S R Skinner; A Venn; C Davies; J Hocking; L Whop; J Leask; K Canfell; L Sanci; M Smith; M Kang; M Temple-Smith; M Kidd; S Burns; L Selvey; D Meijer; S Ennis; C Thomson; N Lane; J Kaldor; R Guy
Journal:  BMC Public Health       Date:  2022-04-25       Impact factor: 4.135

5.  Population-based utility scores for HPV infection and oropharyngeal squamous cell carcinoma among Indigenous Australians.

Authors:  Xiangqun Ju; Karen Canfell; Kirsten Howard; Gail Garvey; Joanne Hedges; Megan Smith; Lisa Jamieson
Journal:  BMC Public Health       Date:  2021-07-26       Impact factor: 3.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.